한스바이오메드
Price Chart
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 349.40B KRW |
| Revenue | 89.78B KRW |
| Net Income | -30.98B KRW |
| Total Assets | 126.41B KRW |
| Net Assets | 33.89B KRW |
| Employees | 247 |
| Value | |
| P/B | 10.31x |
| P/S | 3.89x |
| FCF Yield | -0.48% |
| Profitability | |
| ROE | -91.42% |
| ROA | -24.51% |
| Op. Margin | -33.15% |
| Revenue Growth | 10.65% |
| Financial Health | |
| Debt Ratio | 273.03% |
| Total Debt | 41.30B KRW |
| FCF | -1.69B KRW |
| Cash | 8.15B KRW |
| Current Ratio | 0.69x |
| Dividend | |
| Div. Growth | 0.00% |
| Performance | |
| 1Y Return | 172.83% |
| 1M Return | -15.37% |
| From 52W High | -57.61% |
| 1Y MDD | -58.71% |
| Trading | |
| Volume | 155,600 shares |
| Foreign Own. | 7.12% |
| Per Share | |
| EPS | -1,807 KRW |
| BPS | 5,204 KRW |
Company Info
Established in 1999, this company manufactures and sells human implantable skin, bone graft materials, and medical devices, having been listed on KOSDAQ in 2009. It is the first bio-company in Asia to successfully commercialize human skin, bone, and silicone implant products, receiving South Korea's first human tissue bank establishment license from the Ministry of Food and Drug Safety. The company is expanding its global business through overseas subsidiaries in the United States, Thailand, and the United Kingdom, and continuously increases R&D investments in new medical technology fields such as tissue engineering and vascular hemostatic devices. HansBiomed was established in 1999 and is headquartered in Songpa-gu, Seoul Metropolitan City.